Carbonic anhydrase IX (CA IX) is a target for hypoxic cancer therapies and the discovery of CA IX selective ligands is an imperative for the development of these agents. Primary sulfonamides are broad specificity inhibitors of CA enzymes, while secondary sulfonamides are generally poor CA inhibitors. However, saccharin, a cyclic secondary sulfonamide, has unusually good inhibition of CA IX (K i = 103 nM). In this study we demonstrate that the affinity and selectivity of saccharin for CA IX can be further modulated when linked to hydrophobic or hydrophilic substituents. The hydrophilic glycoconjugate derivative (12) showed improved inhibition of CA IX (K i = 49.5 nM) and extremely poor inhibition of the predominant off-target CAs (K i >50,000 nM), compared to saccharin. This >1,000-fold selectivity for CA IX over off-target CAs is unprecedented for classical primary sulfonamide CA inhibitors. Our study highlights the potential of cyclic secondary sulfonamides to be exploited for the discovery of potent, cancer-selective CA inhibitors.
Introduction
Saccharin (1,2-benzisothiazol-3-one-1,1-dioxide) has been widely used as calorie-free sugar substitute for more than a century 1 and features as a substructure in a number of bioactive compounds, including leukocyte esterase inhibitors and 5-HT 1A agonists, Figure 1 . 2 Our interest in saccharin stems from its ability to inhibit carbonic anhydrase enzymes (CAs), specifically CA IX, Table 1 . 3 CAs catalyze the interconversion of CO 2 and H 2 O with HCO 3 -and a H + to perform a pivotal role in pH regulation. 4 While CA IX expression is lacking in many healthy cells (the stomach and GI tract are exceptions) the expression is upregulated in a wide selection of hypoxic tumors as an aid to survival, proliferation and metastasis in the otherwise hostile tumor microenvironment that results from increased metabolism. 5 There is substantial interest in assessing the impact of disrupting cancer cell pH homeostasis as a therapy, and central to this challenge is the need for selective and efficacious inhibitors of CA IX. 6 It is widely reported that primary sulfonamides (RSO 2 NH 2 ) are excellent inhibitors of CAs and in the greater than 200 protein X-ray crystal structures of this compound class bound to CA II all have the sulfonamide anion (RSO 2 NH -) coordinated to the CA active site zinc cation. 7 In contrast, secondary sulfonamides (RSO 2 NHR′) are generally very poor CA inhibitors, 8 however saccharin as a cyclic secondary sulfonamide is the premier exception to this general finding. To generate CA isozyme selectivity is challenging with primary sulfonamide compounds, and the unusual SAR of saccharin, with an impressive selectivity profile towards CA IX compared to nearly all other CA isozymes (with the exception of CA VII, Table 1 ), is of considerable interest. Although CA VII is strongly inhibited by saccharin, its localization in the CNS likely limits the capacity for saccharin to encounter CA VII in vivo, owing to predicted poor blood-brain barrier permeability of acidic molecules (pK a of saccharin is 1.3) 9 . The structure of human CA II (hCA II) bound to saccharin was reported by Klebe and colleagues in 2007 (PDB entry 2Q38), this structure shows that saccharin utilizes both the sulfonamide and lactam carbonyl groups to form favorable interactions with hCA II. 3a Like primary sulfonamides, saccharin is likely deprotonated with its anionic nitrogen coordinated to the CA active site zinc. The amino acid sequence alignment of CA isozymes indicates that several amino acids are likely responsible for the altered CA selectivity profile of saccharin compared to that for simple primary sulfonamides. 3a We reasoned that improving CA IX binding and selectivity may result from the addition of substituents to the benzene ring of saccharin, which is oriented away from the CA IX active site zinc. In addition to providing insight on SAR, our findings demonstrate the potential of the cyclic secondary sulfonamide motif for the development of effective agents targeting CA IX. Saccharin is a rule-of-three compliant fragment 10 i.e. molecular weight < 300 Da (= 183 Da), clog P ≤ 3 (= 0.45), hydrogen bond donors ≤ 3 (= 1), hydrogen bond acceptors ≤ 3 (= 3) and rotatable bonds ≤ 3 (= 0). Ligand efficiency (LE) is the relationship between a compound's potency and its molecular size, and there are several definitions that represent this ratio, here we will use LE = pKi/MW (MW in kDa). 11 Optimizing potency whilst keeping MW low is important as larger ligands have inherent drawbacks in terms of most physicochemical properties (eg. bioavailability, stability, and solubility) that are relevant to drug discovery.
Perola's early analysis of 60 lead/drug pairs revealed that 90% of drug leads had LE > 12.4 while 90% of drugs had LE > 14. 7. 11b The LE of saccharin binding to CA IX is 38.2, this far exceeds the drug lead and drug thresholds, signifying that the saccharin fragment is a promising starting point for developing CA IX inhibitors. The compact size of the saccharin fragment within the open CA active site architecture (PDB entry 2Q38) allows space for saccharin to be further grown to add interactions with either the hydrophobic half or hydrophilic half of the CA active site. Our interest in saccharin stems from its unusual ability to inhibit CA enzymes. Here we report the design, synthesis and SAR for a panel of saccharin analogues to assess if it is possible to exploit the atypical selectivity profile of saccharin to improve targeting of CA IX over off-target CA isozymes.
Results and Discussion
There are several synthetically distinct methods employed to obtain the saccharin core, with functionalization at either the nitrogen or the carbonyl oxygen readily accomplished either during or post-synthesis, while functionalization elsewhere is more challenging. As we were looking to synthesize analogues of saccharin functionalized on the phenyl ring we hoped to develop a straightforward synthesis that would allow this. Cu(I)-catalyzed azide alkyne cycloaddition (CuAAC) has contributed to a resurgence in the application of azides in the synthesis of more complex molecules across a range of chemistry disciplines.
9-11
Azidosaccharins are not known compounds, however 6-aminosaccharin (3) is a known compound 12 and we approached the synthesis of 6-azidosaccharin (4) by employing the common functional group interconversion of anilines to phenyl azides via a diazonium intermediate. 6-Aminosaccharin (3) was synthesized from p-nitrotoluene (1) in three steps using published procedures, 12 3 was then treated with t-butyl nitrite (1.5 equiv.) and trimethylsilyl azide (1.2 equiv.) to synthesize 6-azidosaccharin (4) (Route A). Metal complexes of saccharin have been described wherein the NH hydrogen is lost (pK a of this hydrogen is 1.3) 9 , and the resulting anion coordinates to the metal(II) cation. 13 Specifically, a crystal structure of a 2:1 saccharin:Cu(II) complex has been reported 14 and related complexes in solution may account for the poor conversion of alkynes a-g and azide 4
to triazole products under the standard CuAAC reaction conditions with catalytic source of Cu(I). Next, with 1.0 equiv of CuSO 4 •5H 2 O, 2.0 equiv of sodium ascorbate and a higher reaction temperature of 60 °C, we were able to demonstrate conversion to triazoles, however both the 1,4-disubstituted and 1,5-disubstituted-1,2,3-triazoles were formed. Work up of these reactions required challenging chromatography to separate regioisomers, this was further hampered by the increased amount of CuSO 4 •5H 2 O, and sodium ascorbate used for the reaction. Nevertheless, we were able to prepare 1,4-disubstituted triazoles 5a and 5b using this method, isolated yields were 43% and 33%, respectively. With the intention to improve our synthetic methodology we explored the use of an NHprotected 6-azidosaccharin as an alternate approach to the target compounds 5a-5g. This NHprotected compound should allow standard CuAAC conditions to be used to form the triazole link, with subsequent removal of the NH protecting group from the purified saccharin-triazole product. The synthesis of the saccharin heterocycle may be achieved by the direct oxidation of 2-methyl benzenesulfonamide using the H 5 IO 6 -CrO 3 as the oxidation system. Xu and colleagues investigated these oxidation conditions with a number of N-alkyl-otoluenesulfonamides, and were able to show that oxidation of N-t-butyl-2-methyl-5-nitrobenzenesulfonamide with H 5 IO 6 -CrO 3 in acetonitrile gave the corresponding N-t-butyl saccharin compound (N-t-butyl-6-nitro-1,2-benzisothiazole-3-one-1,1-dioxide, 6) in 88% yield (62% yield after recrystallization). This good yield and straightforward purification encouraged us to utilize the t-butyl moiety as a protecting group strategy, with removal of the group under acidic conditions as a final step in the synthesis of target compounds. 15 The synthetic route using this NH-t-butyl-protected azidosaccharin approach is depicted in Scheme 1 (Route B).
The synthesis of 5a-5g from compound 6 comprises four steps, while compound 6 is itself synthesized from p-nitrotoluene in two steps. 16 Compound 6 was reduced with H 2 , 10% Pd/C to give the new compound, 6-amino-2-N-t-butyl saccharin/N-t-butyl-6-amino-1,2-benzisothiazole-3-one-1,1-dioxide (7) . The amino function of 7 was next converted into the azido group using t-butyl nitrite and trimethylsilyl azide to give the new compound N-t-butyl-6-azido-1,2-benzisothiazole-3-one-1,1-dioxide (8) with variable isolated yields (23% and 89%). Long reaction times (between 4 -7 days) were needed for this final reaction to complete, however the relative ease of workup compared to the initial approach (Route A) compensated for the extended reaction times.
In the past few years, our group has synthesized a large collection of glycoconjugate CA inhibitors, wherein the hydrophilic carbohydrate moiety is employed to reduce the inhibitors Log P. 17 The calculated log P (cLog P) parameter generally provides a good correlation with experimental permeability data 18 and molecules with cLog P values between 1 and 3 typically have good passive membrane permeability properties while those with cLogP values of < 0 are more likely to have a low capacity for penetrating cell membranes. Herein, we have designed and synthesized the saccharin glycoconjugate 12, Figure 2 , in order to compare the CA inhibition profile with less hydrophilic compounds 5a-5g. The cLog P for the saccharin glycoconjugate 12 is -2.30, compared to values of +2.09 to +3.06 for 5a-5f, CA Inhibition. One goal of this study was to generate compounds that would enable us to assess if it was possible to exploit the atypical selectivity profile of saccharin to improve targeting of CA IX over the two major off-target CA isozymes (I and II). In addition to CA IX expression, CA XII expression is upregulated in a wide selection of hypoxic tumors, so it is of general interest to also monitor also for inhibition of CA XII to provide a comprehensive understanding of any individual compounds potential as a cancer therapeutic. The CA inhibition data to block the interconversion of CO 2 with HCO 3 -and a H + , for the saccharintriazole analogues 5a-5g and 12, the simple saccharin analogues 2, 3 and 4, as well as saccharin itself as a reference compound were measured for CA I, II, IX and XII, results are presented in Table 2 . The selectivity ratios for CA IX and CA XII inhibition over the offtarget CA I and CA II are presented in Table 2 . Selectivity is determined by the ratio of K i s for CA isozyme relative to CA IX and XII.
Saccharin, the reference compound for SAR, has a K i of 103 nM for CA IX and is 180-fold selective over CA I and 58-fold selective over CA II, while for the other cancer-associated CA, CA XII, the K i of saccharin is 633 nM, much weaker inhibition than for CA IX. Saccharin thus has better CA IX selectivity than CA XII selectivity (29-and 9-fold for CA I and II, respectively). Noticeably the simple nitro and amino saccharin derivatives, compounds 2 and 3, as well as the hydrophilic glycoconjugate 12 had extremely poor inhibition of CA I and II (>50, 000 nM) while 2 and 12 were equal or better inhibitors of CA IX than saccharin, with K i s of 95.8 and 49.5 nM respectively. This SAR is ideal as it leads to very high selectivity for CA IX over both off-target CAs, >522-fold for 2 and >1,010-fold for 12. This selectivity is substantially higher than for the reported primary benzene sulfonamide class of CA inhibitors, signifying that compounds 2 and 12 are excellent candidates for follow-up cell based studies.
For the phenyl triazole substituted saccharin compounds 5a-5f, the SAR was related to the substitution on the phenyl ring, compounds typically displayed very weak inhibition of offtarget CA I and II. For CA I, inhibition was very poor with K i s >50, 000 nM for 5a, 5b and 5e, while for CA II the K i s were similarly weak (>50, 000 nM) for 5c and 5d. For 5a-5e the inhibition of the other off-target CA, although greater was still weak with K i s ranging from 4,870 to 9,315 nM. For CA IX a methyl substituent on the phenyl ring gave the best inhibition, with K i s below 100 nM for 5b, 5e and 5f. Similarly for CA XII the 3-methyl substitution of 5b and 5e also gave K i s below 100 nM. Compound 5g comprises a primary sulfonamide group in addition to the secondary sulfonamide group of the saccharin fragment. It is expected that the primary sulfonamide group of 5g will dominate the recognition interaction with the CAs, and inhibition data supports this assumption as 5g is the most potent CA inhibitor at all isozymes tested. When comparing compound 5g with 5a the difference in structure is a primary sulfonamide moiety versus a hydrogen atom, respectively, this compound pair thus allows the impact of the primary sulfonamide-CA IX interaction to be disconnected in part from the saccharin-CA IX interaction. Compound 5g (K i = 8.6 nM at CA IX) has 56-fold greater activity than for 5a (K i = 484 nM at CA IX). Our findings present the first report that to the best of our knowledge has investigated the SAR of the saccharin fragment against cancer-relevant CA IX, with a single earlier study reporting data only at off-target CA I and CA II. Density maps were generated using the FFT algorithm in the CCP4 suite 6.3. 20 The figures were prepared using PyMol. 21 Coordinates and structure factors for CA II:5b have been deposited with the PDB (accession code 4cq0).
Conclusion
Saccharin as a cyclic secondary sulfonamide is an exception to the general finding that 
Experimental Section
Compound Synthesis. All reagents were purchased from commercial suppliers. All reactions were monitored by TLC, TLC plates were visualized with UV fluorescence (λ = 254 nm).
Silica gel flash chromatography was performed using silica gel 60 Å (230-400 mesh is consistent with preparation by General Procedure 1 (above).
N-t-Butyl-6-amino-1,2-benzisothiazole-3-one-1,1-dioxide (7). The title compound (7) 
N-t-Butyl-6-azido-1,2-benzisothiazole-3-one-1,1-dioxide (8) To a suspension of N-t-butyl-6-
amino-1,2-benzisothiazole-3-one-1,1-dioxide (7, 240 mg, 0.94 mmol, 1.0 equiv.) in anhydrous acetonitrile (2.6 mL) at 0 °C was added t-butyl nitrite (168 µL, 1.5 equiv.) and azidotrimethylsilane (150 µL, 1.2 equiv.) by dropwise addition. The reaction mixture was stirred at 0 °C for one hour, warmed to room temperature for 16 h after which TLC (EtOAc/hexane, 1:2) showed reaction was complete. dry compound was added to the crystallization drop after crystals had formed and several days before data were collected. 360 frames of one degree oscillation were taken at the MX-2 beamline of the Australian Synchrotron. The data were indexed using XDS 24 and scaled using SCALA. 25 Molecular replacement was done using Phaser 26 using 3ML2 as the initial starting model. The model was manually rebuilt using Coot 27 and refined using Refmac. 28 The compound was placed in density using the program Afitt (OpenEye Scientific Software) and further refined using Refmac. 
CA Inhibition
Assay. An Applied Photophysics stopped-flow instrument was used for assaying the CA-catalyzed CO 2 hydration activity. 29 IC 50 values were obtained from dose response curves working at seven different concentrations of test compound, by fitting the curves using PRISM (www.graphpad.com) and non-linear least squares methods, values represent the mean of at least three different determinations as described by us previously. 30 The inhibition constants (K i ) were then derived by using the Cheng-Prusoff equation, 31 and 12. Data collection and structure refinement statistics of 5b:hCA II crystal structure. This material is available free of charge via the Internet at http://pubs.acs.org.
